(0.17%) 5 108.87 points
(0.17%) 38 304 points
(0.17%) 15 955 points
(-1.13%) $82.90
(5.15%) $2.02
(0.07%) $2 348.90
(0.04%) $27.55
(3.98%) $958.80
(-0.17%) $0.933
(-0.25%) $11.00
(-0.45%) $0.797
(1.74%) $93.47
@ $3.79
发出时间: 15 Feb 2024 @ 02:46
回报率: -20.06%
上一信号: Feb 14 - 22:30
上一信号:
回报率: -3.33 %
Live Chart Being Loaded With Signals
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma...
Stats | |
---|---|
今日成交量 | 232 683 |
平均成交量 | 2.24M |
市值 | 365.35M |
EPS | $0 ( 2024-02-27 ) |
下一个收益日期 | ( $-0.180 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.720 |
ATR14 | $0.00700 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Alleva Lawrence M | Buy | 3 996 | Stock Option (right to buy) |
2024-01-13 | Mandelia Ashish | Buy | 0 | |
2024-01-15 | Protopapas Anna | Buy | 17 708 | Common Stock |
2024-01-15 | Protopapas Anna | Buy | 21 250 | Common Stock |
2024-01-16 | Protopapas Anna | Sell | 29 399 | Common Stock |
INSIDER POWER |
---|
74.95 |
Last 98 transactions |
Buy: 4 017 838 | Sell: 585 969 |
音量 相关性
Mersana Therapeutics Inc 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Mersana Therapeutics Inc 相关性 - 货币/商品
Mersana Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $36.86M |
毛利润: | $35.34M (95.88 %) |
EPS: | $-1.480 |
FY | 2023 |
营收: | $36.86M |
毛利润: | $35.34M (95.88 %) |
EPS: | $-1.480 |
FY | 2022 |
营收: | $26.58M |
毛利润: | $25.65M (96.51 %) |
EPS: | $-2.22 |
FY | 2021 |
营收: | $43 000.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-2.37 |
Financial Reports:
No articles found.
Mersana Therapeutics Inc
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。